Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer

Urologic Clinics of North America

Volumn 39, Issue 4, 2012, Pages 547-560

  Lin, Jianqing ^a   Kelly, William K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Prostate cancer; Treatment

Indexed keywords

AFLIBERCEPT; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CABAZITAXEL; CABOZANTINIB; CEDIRANIB; CILENGITIDE; DENOSUMAB; DOCETAXEL; ENOXAPARIN; ENZALUTAMIDE; ENZASTAURIN; ESTRAMUSTINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENALIDOMIDE; NSC 707544; PI 88; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; SORAFENIB; SUNITINIB; TANESPIMYCIN; TASQUINIMOD; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG CANCER; MAINTENANCE THERAPY; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANILIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; MALE; PROSTATIC NEOPLASMS; PYRIDINES; PYRROLES; SIGNAL TRANSDUCTION; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867690624     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.07.010     Document Type: Review

References (75)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
3. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001, 28(6):536-542.
4. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003, 2(4 Suppl 1):S127-S133.
5. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3(6):401-410.
6. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
7. Alfiky A., Kelly W.K. Bevacizumab in advanced prostate cancer. Drug management of prostate cancer 2010, 207-214. Springer, ISBN: 978-1603278317. W.D. Figg, C.H. Chau, E.J. Small (Eds.).
8. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358(19):2039-2049.
9. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
10. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010, 60(4):222-243.
11. Movsas B., Chapman J.D., Horwitz E.M., et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999, 53(1):11-18.
12. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835.
13. Lin J., Denmeade S., Carducci M.A. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Curr Cancer Drug Targets 2009, 9(7):881-887.
14. Weidner N., Carroll P.R., Flax J., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409.
15. Strohmeyer D., Rossing C., Strauss F., et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42(1):26-33.
16. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
17. Mabjeesh N.J., Willard M.T., Frederickson C.E., et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003, 9(7):2416-2425.
18. Kimbro K.S., Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006, 13(3):739-749.
19. Boddy J.L., Fox S.B., Han C., et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005, 11(21):7658-7663.
20. Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19(4):1207-1225.
21. Mao K., Badoual C., Camparo P., et al. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy. Can J Urol 2008, 15(5):4257-4262.
22. Ferrer F.A., Miller L.J., Lindquist R., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999, 54(3):567-572.
23. Ferrer F.A., Miller L.J., Andrawis R.I., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997, 157(6):2329-2333.
24. Duque J.L., Loughlin K.R., Adam R.M., et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54(3):523-527.
25. Duque J.L., Loughlin K.R., Adam R.M., et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 2006, 61(5):401-408.
26. Bok R.A., Halabi S., Fei D.T., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001, 61(6):2533-2536.
27. George D.J., Halabi S., Shepard T.F., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005, 11(5):1815-1820.
28. Khasraw M., Pavlakis N., McCowatt S., et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 2010, 21(6):1302-1307.
29. Sasisekharan R., Shriver Z., Venkataraman G., et al. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2(7):521-528.
30. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30(13):1534-1540.
31. Michaelson M., Oudard S., Ou Y., et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011, 29(Suppl). [abstr 4515].
32. Zurita A.J., George D.J., Shore N.D., et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 2012, 23(3):688-694.
33. Sonpavde G., Periman P.O., Bernold D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21(2):319-324.
34. Dahut W.L., Scripture C., Posadas E., et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008, 14(1):209-214.
35. Chi K.N., Ellard S.L., Hotte S.J., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008, 19(4):746-751.
36. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004, 22(13):2532-2539.
37. Figg W.D., Retter A.S., Steinberg S.M., et al. In reply to: inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?. J Clin Oncol 2005, 23(9):2113.
38. Figg W.D., Li H., Sissung T., et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007, 99(5):1047-1055.
39. Ning Y.M., Gulley J.L., Arlen P.M., et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28(12):2070-2076.
40. Olsson A., Bjork A., Vallon-Christersson J., et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010, 9:107.
41. Dreicer R., Garcia J., Hussain M., et al. Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs 2011, 29(6):1441-1448.
42. Alva A., Slovin S., Daignault S., et al. Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012, 30(2):749-757.
43. Gasparini G., Longo R., Fanelli M., et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005, 23(6):1295-1311.
44. Heldin C.H., Rubin K., Pietras K., et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4(10):806-813.
45. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
46. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13(2):159-167.
47. Cheng L., Zhang S., Sweeney C.J., et al. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 2004, 24(4):2135-2140.
48. Stewart R.J., Panigrahy D., Flynn E., et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001, 165(2):688-693.
49. Hsu J.Y., Wakelee H.A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009, 23(5):289-304.
50. Hainsworth J.D., Spigel D.R., Farley C., et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007, 25(13):1747-1752.
51. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25(30):4743-4750.
52. Thomas M.B., Morris J.S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(6):843-850.
53. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27(13):2231-2237.
54. Lubner S.J., Mahoney M.R., Kolesar J.L., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol 2010, 28(21):3491-3497.
55. Ross R.W., Galsky M.D., Febbo P., et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a prostate Cancer Clinical Trials Consortium trial. Cancer 2012, [Epub ahead of print].
56. Rini B.I., Weinberg V., Fong L., et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006, 107(1):67-74.
57. Di Lorenzo G., Figg W.D., Fossa S.D., et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008, 54(5):1089-1094.
58. Picus J., Halabi S., Kelly W.K., et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011, 117(3):526-533.
59. Zuniga R.M., Torcuator R., Jain R., et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010, 99(2):237-242.
60. Freedman A.N., Sansbury L.B., Figg W.D., et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 2010, 102(22):1698-1705.
61. Kim D.H., Xu W., Kamel-Reid S., et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010, 21(6):1179-1188.
62. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91(9):4082-4085.
63. Kenyon B.M., Browne F., D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997, 64(6):971-978.
64. Efstathiou E., Troncoso P., Wen S., et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007, 13(4):1224-1231.
65. Adesunloye B., Huang X., Ning Y.M., et al. Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012, 30(Suppl 5). [abstr 207].
66. Puente J., Manzano A., Martin M., et al. Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Anticancer Drugs 2010, 21(Suppl 1):S19-S22.
67. Bozec A., Sudaka A., Toussan N., et al. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009, 20(10):1703-1707.
68. Qvortrup C., Jensen B.V., Jorgensen T.L., et al. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncol 2010, 49(6):833-836.
69. Yeramian A., Sorolla A., Velasco A., et al. Inhibition of activated receptor tyrosine kinases by sunitinib induces growth arrest and sensitizes melanoma cells to bortezomib by blocking Akt pathway. Int J Cancer 2012, 130(4):967-978.
70. Zurita A., Ward J.F., Araujo J.C., et al. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 2008, 26(Suppl). [abstr 16004].
71. Dror Michaelson M., Regan M.M., Oh W.K., et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009, 20(5):913-920.
72. Verras M., Lee J., Xue H., et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67(3):967-975.
73. Varkaris A., Corn P.G., Gaur S., et al. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 2011, 20(12):1677-1684.
74. Bottaro D.P., Rubin J.S., Faletto D.L., et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251(4995):802-804.
75. Oto A., Yang C., Kayhan A., et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 2011, 197(6):1382-1390.